Emepi-CMP001

Research and development advanced in December 2024, with the testing to determine the efficacy and effectiveness in treatment to Moderate and Severe Aches, Pains and Discomfort of a body for a Preminilary confirmational bias and placebo tests on a previous Surgical Injury [3rd degree open Olecranon Surgery].

Filled and Submitted an IND and NDA with the FDA with the DIOIC's Contact with the FDA.

Conclusion to the 5 day 'tree-bark' study shows a positive correlation to relieve of moderate to severe pain with CMP001-Emepi; with an increase in mobility of affected area, relief of pain from moderate to severe to slight to none registration of pain and reduction in stiffness of the affected area. Within the study, a dosage requirement was actuated for both the intravenous medication and the pill form of the medication CMP001, a test for effects, and on record, the numbing and chilling of the affected area i.e., the injured area and the entire part of the arm affected. This study leads to the conclusion of a 5 - day study to test effects, effectiveness, dosage and efficasy, with data records submitted to the FDA and Veterans Affairs Administration of the United States of America with a purchase order request documentation fulfilled. Study evaluated the Injury of a patient from a 3rd Degree open Olecranon Surgery and results.